rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    FBT
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Better Biotech ETF: First Trust's FBT vs. Invesco's PBE | The Motley Fool

      Both biotech ETFs hold about 30 healthcare names, but their index methods and fees differ enough to shape results for investors weighing sector exposure.

      Nov 14The Motley FoolIVZFBT
      Two Ways to Play Biotech: FBT’s Return Edge vs. IBB’s Cost Advantage | The Motley Fool

      Fewer holdings, a higher fee, and a shallower drawdown set these two biotech funds apart in ways that could matter for long-term investors.

      Nov 14The Motley FoolIBBFBT
      Drug Makers or Biotech Bets: Which ETF Is the Better Buy, State Street’s XPH or First Trust’s FBT? | The Motley Fool

      One fund holds about 60 drug companies at a lower fee. The other holds 30 biotech names and has a stronger long-term record. Either way, expect some volatility.

      Nov 11The Motley FoolSTTFBTXPH
      Which Is the Better Buy: iShares’ Pharma ETF IHE or First Trust’s Biotech Fund FBT? | The Motley Fool

      iShares offers lower fees and smoother returns, while First Trust provides concentrated biotech exposure with higher growth potential.

      Nov 11The Motley FoolFBTIHE
      Which Healthcare ETF Is the Better Buy: Simplify’s Mission-Driven PINK or First Trust’s Biotech FBT? | The Motley Fool

      PINK offers broad active healthcare exposure with lower volatility, while FBT's concentrated biotech play delivered stronger 1-year returns but carries steeper drawdown risk.

      Oct 27The Motley FoolFBTPINK
      Which Healthcare ETF Is the Better Buy: Invesco’s Broad RSPH or First Trust’s Biotech FBT? | The Motley Fool

      FBT has outperformed RSPH by a wide margin recently. The question is whether you want to own the fund that won last year or the one built to hold up over many years.

      Oct 26The Motley FoolIVZFBTRSPH
      Which Healthcare ETF Is the Better Buy: iShares’ Global IXJ or First Trust’s Biotech FBT? | The Motley Fool

      IXJ offers diversified global exposure at lower cost, while FBT concentrates on biotech with higher volatility and stronger recent returns.

      Oct 26The Motley FoolFBTIXJ
      What First Trust NYSE Arca Biotech (FBT) Bought: Tarsus Leads on Oct. 16

      The fund bought $90.7 million of Tarsus Pharmaceuticals as a new position, part of $516.5 million in gross trading and $80.2 million in net buying.

      Oct 20Yahoo FinanceFBT
      Better Biotechnology ETF: First Trust FBT vs. VanEck BBH | The Motley Fool

      VanEck's lower 0.35% expense ratio appeals to cost-conscious investors, while First Trust's $2.9 billion in assets and equal-weighted approach offer broader diversification across 30 biotech holdings.

      Oct 10The Motley FoolBBHDESKFBT
      Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets - ARK Genomic Revolution ETF (BATS:ARKG)

      Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.

      Sep 22BenzingaARKGQNDXFBTXBI
      Which Is the Better Healthcare ETF: Fidelity's Low-Cost FHLC or First Trust's High-Conviction FBT? | The Motley Fool

      One fund offers broad sector exposure at 0.08% cost; the other concentrates on 30 biotech stocks with higher volatility but stronger recent returns.

      Sep 10The Motley FoolFBTFHLC

      This is the newest page. Registered accounts read further back.